source
- Attovia, Braveheart Bio, and Vogenx aim to raise over $500M through combined IPOsAttovia Therapeutics, Braveheart Bio and Vogenx have each filed IPO paperwork, setting price ranges that together target more than $500 million in gross proceeds from public investors. Braveheart…
- Legend Biotech CEO Ying Huang resigns abruptly, board taps interim leaderLegend Biotech announced that its chief executive, Dr. Ying Huang, has stepped down unexpectedly, leaving the role vacant. Huang, who moved from chief financial officer to CEO in 2020 after a cust…